Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib in MET Exon 14 Mutated NSCLC
NCT04923945Phase 3Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Aug 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of savolitinib in non-small cell lung cancer (NSCLC), sponsored by Hutchison MediPharma (HMP). Started Aug 2021; status: completed.
02
Drugs
savolitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04923945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04923945.